熱門資訊> 正文
    
 Candel Therapeutics宣布直接发行1500万美元
 
        2025-06-24 21:19
      
  
 
 
  - Candel Therapeutics (NASDAQ:CADL) is selling ~3.2M shares at $4.67 each in a registered direct offering.
  
  - The offering is expected to close on June 25, 2025, with gross proceeds of around $15M before expenses.
  
  - Investors include healthcare-focused institutions, company executives, and board members.
  
  - Funds will support pre-commercialization and launch readiness for CAN-2409 in prostate cancer, pending regulatory approval.
  
  - Proceeds will also be used for medical affairs, BLA preparation expected in Q4 2026, and general corporate purposes.
  
  - Source: Press release 
  
 
 
  
  More on Candel Therapeutics
 
   
   - Candel Therapeutics: CAN-2409's Promising Progress Deserves An Upgrade
  
   - Candel gains after FDA RMT designation for lead asset
  
   - Candel Therapeutics GAAP EPS of $0.13
  
   - Seeking Alpha’s Quant Rating on Candel Therapeutics
  
   - Historical earnings data for Candel Therapeutics
  
  
 
       
    風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。